Anteris Technologies Secures $320 Million for PARADIGM Trial

Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialAnteris Technologies Global Corp. ( (AVR) ) has shared an announcement. On January 22, 2026, Anteris Technologies Global Corp. and Medtronic announced that Anteris had completed a $90 million strategic equity investment from Medtronic, immediately following an underwritten offering of common stock, for total gross proceeds of $320 million. The capital raise is intended to support execution of Anteris’ global pivotal PARADIGM trial and advance the company toward commercialization of its DurAVR® Transcatheter Heart Valve, reinforcing a strategic alignment between the two companies in reshaping the transcatheter aortic valve replacement market. The PARADIGM Trial, which began enrolling and implanting its first patients in the fourth quarter of 2025, is a head‑to‑head, prospective randomized controlled study of about 1,000 patients comparing DurAVR® to existing commercial TAVR valves on key outcomes including mortality, stroke and cardiovascular hospitalization at one year, positioning Anteris to generate pivotal clinical evidence for its technology and potentially strengthen its competitive position in structural heart therapies. The most recent analyst rating on (AVR) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page. Spark’s Take on AVR Stock According to Spark, TipRanks’ AI Analyst, AVR is a Neutral. The score is held back primarily by weak financial performance (declining revenue, large losses, and negative cash flow). Technicals and recent corporate events are constructive (price above key averages, positive MACD, and meaningful clinical/regulatory milestones), but valuation remains challenging due to ongoing losses and no dividend support. To see Spark’s full report on AVR stock, click here. More about Anteris Technologies Global Corp. Anteris Technologies Global Corp., listed on Nasdaq and the ASX under ticker AVR, is a global structural heart company focused on designing, developing and commercializing medical devices to restore healthy heart function. Founded in Australia and operating with a significant presence in Minneapolis, it leads with its DurAVR® Transcatheter Heart Valve system, a balloon‑expandable, biomimetic valve using the company’s patented ADAPT® anti‑calcification tissue technology, aimed at treating aortic stenosis and supported by more than a decade of clinical use of its tissue platform. Average Trading Volume: 525,971 Technical Sentiment Signal: Strong Buy Current Market Cap: $236.9M For an in-depth examination of AVR stock, go to TipRanks’ Overview page.